Recommendations on the selection of strains to be included in an influenza virus vaccine for the 2019 Southern Hemisphere influenza season

1) Approaches for demonstrating effectiveness of group B streptococcus (GBS) vaccines intended for use in pregnant women to protect the newborn infant

2) Overview of the research program in the Laboratory of Respiratory Viral Diseases (LRVD), Division of Viral Products, Office of Vaccines Research and Review, CBER, FDA

1) Recommendations on the selection of strains to be included in the influenza virus vaccines for the 2018-2019 U.S. influenza season 2) Overview of the research program in the Laboratory of Mucosal Pathogens and Cellular Immunology (LMPCI), Division of Bacterial, Parasitic and Allergenic Products (DBPAP), Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER), FDA

Recommendations on the clinical development plan for Pfizer’s investigational Staphylococcus aureus vaccine intended for pre-surgical prophylaxis in elective orthopedic surgical populations

Recommendations on the selection of strains to be included in an influenza virus vaccine for the 2018 Southern Hemisphere influenza season

Zoster Vaccine Recombinant, Adjuvanted, manufactured by GlaxoSmithKline Biologicals

HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)] by Dynavax Technologies Corp.

Considerations for evaluation of Respiratory Syncytial Virus vaccines in seronegative infants

Recommendations on the selection of strains to be included in the influenza virus vaccines for the 2017-2018 influenza season